Diabetes, insulin resistance, and HIV

Current Infectious Disease Reports

Volumn 8, Issue 1, 2006, Pages 69-75

  Hadigan, Colleen ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; GLUCOSE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; METFORMIN; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; ZIDOVUDINE;

AGING; BODY FAT DISTRIBUTION; BODY MASS; CLINICAL TRIAL; COMORBIDITY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG POTENTIATION; DRUG SUBSTITUTION; EXERCISE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INSULIN RESISTANCE; INTERMETHOD COMPARISON; LIFESTYLE; LIPOATROPHY; LOW DRUG DOSE; MITOCHONDRIAL TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; WAIST CIRCUMFERENCE;

EID: 31544460374     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0037-1     Document Type: Review

References (44)

1. Hadigan C, Meigs JB, Corcoran C, et al.: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-139.
2. Brown TT, Cole SR, Li X, et al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005, 165:1179-1184.
3. Justman JE, Benning L, Danoff A, et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-Infected women. J Acquir Immune Defic Syndr 2003, 32:298-302.
4. Friis-Moller N, Sabin CA, Weber R, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
5. Hadigan C, Miller K, Corcoran C, et al.: Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999, 84:1932-1937.
6. Hadigan C, Corcoran C, Stanley T, et al.: Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000, 85:35-41.
7. Walli R, Herfort O, Michl GM, et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-173.
8. Carr A, Samaras K, Thorisdottir A, et al.: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
9. Howard AA, Floris-Moore M, Arnsten JH, et al.: Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005, 40:1492-1499.
10. Danoff A, Shi Q, Justman J, et al.: Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr 2005, 39:55-62.
11. Bitnun A, Sochett E, Dick PT, et al.: Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005, 90:168-174.
12. Beregszaszi M, Dollfus C, Levine M, et al.: Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005, 40:161-168.
13. Mehta SH, Brancati FL, Sulkowski MS, et al.: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000, 133:592-599.
14. Visnegarwala F, Chen L, Raghavan S, Tedaldi E: Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect 2005, 50:331-337.
15. Mynarcik DC, McNurlan MA, Steigbigel RT, et al.: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000, 25:312-321.
16. Mallal SA, John M, Moore CB, et al.: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309-1316.
17. Brown TT, Li X, Cole SR, et al.: Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005, 19:1375-1383.
18. Meininger G, Hadigan C, Rietschel P, Grinspoon S: Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr 2002, 76:460-465.
19. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, et al.: Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001, 15:1993-2000.
20. Hadigan C, Kamin D, Liebau J, et al.: Depot specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 2005, Epublished August 30, 2005.
21. Lagathu C, Bastard JP, Auclair M, et al.: Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004, 9:911-920.
22. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
23. Noor MA, Lo JC, Mulligan K, et al.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15:F11-18.
24. Noor MA, Seneviratne T, Aweeka FT, et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1-8.
25. Noor MA, Parker RA, O'Mara E, et al.: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004, 18:2137-2144.
26. Petersen KF, Dufour S, Befroy D, et al.: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54:603-608.
27. Hadigan C, Borgonha S, Rabe J, et al.: Increased rates of lipolysis among HIV-infected men receiving highly active antiretroviral therapy. Metabolism 2002, 51:1143-1147.
28. Sekhar RV, Jahoor F, White AC, et al.: Metabolic basis of HIV-Iipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002, 283:E332-337.
29. Gan SK, Samaras K, Thompson CH, et al.: Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002, 51:3163-3169.
30. Reeds DN, Yarasheski KE, Fontana L, et al.: Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab 2005, Epublished August 23, 2005.
31. Hadigan C, Rabe J, Meininger G, et al.: Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr 2003, 77:490-494.
32. Saint-Marc T, Touraine JL: Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999, 13:1000-1002.
33. Tomazic J, Karner P, Vidmar L, et al.: Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta Dermatovenerol Alp Panonica Adriat 2005, 14:99-105.
34. Hadigan C, Corcoran C, Basgoz N, et al.: Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000, 284:472-477.
35. Hadigan C, Yawetz S, Thomas A, et al.: Metabolic effects of rosiglitazone in HIV lipodystrophy: A randomized controlled trial. Ann Intern Med 2004, 140:786-794.
36. van Wijk JP, de Koning EJ, Cabezas MC, et al.: Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005, 143:337-346.
37. Carr A, Workman C, Carey D, et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet 2004, 363:429-438.
38. Sutinen J, Hakkinen AM, Westerbacka J, et al.: Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Thor 2003, 8:199-207.
39. Tebas P, Yarasheski K, Henry K, et al.: Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004, 20:589-594.
40. Carr A, Workman C, Smith DE, et al.: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002, 288:207-215.
41. Gavrila A, Tsiodras S, Doweiko J, et al.: Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. Clin infect Dis 2003, 36:1593-1601.
42. Yarasheski KE, Tebas P, Stanerson B, et al.: Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol 2001, 90:133-138.
43. Driscoll SD, Meininger GE, Lareau MT, et al.: Effects of exercise training and metformin on body composition and cardiovascular indices in HIV infected patients. AIDS 2004, 18:465-473.
44. Martinez E, Domingo P, Ribera E, et al.: Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antiviral Therapy 2003, 8:403-410.